Autres langues Otsuka Holdings Co., Ltd.

Actions

4578

JP3188220002

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
6 370 ^JPY	+1,56%		+2,97%	+20,44%

09/04	H. Lundbeck et Otsuka Pharmaceutical cherchent à obtenir le feu vert de la FDA pour une thérapie combinée contre le SSPT	MT
02/04	Bourses asiatiques: Tokyo mi-figue, mi-raisin, Hong Kong confiante	AW

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	09/04
Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation	29/03
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	27/03
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical	18/03
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors	07/03
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka	26/02
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses	16/02
Otsuka Holdings Co., Ltd. Provides Year-End Dividend Guidance for the Fiscal Year Ending December 31, 2024	16/02
Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending December 31, 2024	16/02
MÄRKTE ASIEN/Schwach - Zinssenkungshoffnungen schwinden	14/02
MÄRKTE ASIEN/Leichter nach US-Dämpfer für Zinssenkungshoffnungen	14/02
Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024	14/02
Otsuka Holdings Lowers 2023 Profit Outlook	13/02
Japan's Nikkei cruises to 34-year peak, briefly breaching 38,000 range	13/02
Japan's Nikkei soars to 34-year high on chip shares, earnings	13/02
Phase 3 Trial for Otsuka's Alzheimer's-related Agitation Treatment Fails to Meet Primary Endpoint	13/02
Otsuka's drug for Alzheimer's disease agitation fails in late stage study	13/02
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ended December 31, 2023	13/02
Otsuka Group Selected for CDP Climate Change a List for a Second Consecutive Year	08/02
Ionis Pharmaceuticals Says Potential Angioedema Treatment Met Primary Endpoint of Phase 3 Study	22/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Otsuka Holdings Co., Ltd.

Actions

4578

JP3188220002

Autres langues

Filtres